We provide you with 20 years of free, institutional-grade data for APGN stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of APGN. Explore the full financial landscape of APGN stock.
| Reported Date | CIK | Ticker | Type |
|---|
Apexigen, Inc.(NASDAQ:APGN) 
Apexigen Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical development for the treatment of solid tumors, such as mela...
Website: https://www.apexigen.com
Founded: 2010
IPO Price: $10 (Jul 29, 2022)
Full Time Employees: 22
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report about APGN stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.